Cassava Sciences, Inc.
(NASDAQ : SAVA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 1.19%246.411.5%$948.38m
MRNAModerna, Inc. -0.32%141.740.0%$803.33m
REGNRegeneron Pharmaceuticals, Inc. 1.67%604.342.6%$520.58m
VRTXVertex Pharmaceuticals, Inc. 1.43%280.111.9%$508.93m
GILDGilead Sciences, Inc. 0.13%62.291.0%$508.40m
NVAXNovavax, Inc. 1.20%51.6775.7%$422.12m
ILMNIllumina, Inc. -1.24%185.113.3%$353.11m
BIIBBiogen, Inc. 1.06%204.661.8%$244.75m
SNSSSunesis Pharmaceuticals, Inc. 1.80%3.400.7%$237.67m
CRSPCRISPR Therapeutics AG -0.84%62.750.6%$168.47m
BNTXBioNTech SE 0.55%140.600.0%$167.82m
BMRNBioMarin Pharmaceutical, Inc. 0.17%83.304.2%$123.73m
EXASEXACT Sciences Corp. -1.70%40.4117.7%$97.80m
TECHBio-Techne Corp. -0.67%343.684.5%$92.59m
IOVAIovance Biotherapeutics, Inc. -3.55%10.590.0%$92.25m

Company Profile

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.